📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Reversal of behavioural phenotype by the cannabinoid-like compound VSN16R in fragile X syndrome mice. (2022)

First Author: Hurley MJ

Attributed to: Biomedical Catalyst – Drug product production, clinical support studies, and phase 1 trial of a new MS drug funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/brain/awab246

PubMed Identifier: 34196695

Publication URI: http://europepmc.org/abstract/MED/34196695

Type: Journal Article/Review

Volume: 145

Parent Publication: Brain : a journal of neurology

Issue: 1

ISSN: 0006-8950